The U.S. Food and Drug Administration (FDA) has granted CooperVision approval for its new Biofinity® toric multifocal contact lenses.
The highly-anticipated product combines the proven optical designs of CooperVision’s Biofinity® toric—the most prescribed toric lens on the market1—and Biofinity® multifocal to provide patients with the combined astigmatism and presbyopia vision correction they deserve. The company plans to make the lenses available to U.S. eye care professionals later this year, followed by other markets.
“Biofinity® toric multifocal extends the reliable performance of our Biofinity® toric lenses to presbyopic patients,” said Michele Andrews, OD, Senior Director, Professional and Academic Affairs, North America, CooperVision “U.S. eye care professionals will soon have an easy-to-fit, familiar lens design they can count on to keep current toric wearers satisfied in contact lenses for longer, and provide new astigmatic wearers an alternative to reading glasses. It’s a win-win for practitioners and their patients.”
Lens parameters and other details regarding Biofinity® toric multifocal will be made public in the coming months.
